Pathogenic Cycle Between the Endogenous Nitric Oxide Synthase Inhibitor Asymmetrical Dimethylarginine and the Leukocyte-Derived Hemoprotein Myeloperoxidase
Author(s) -
Eike-Christin von Leitner,
Anna Klinke,
Dorothee Atzler,
Jessica L. Slocum,
Natalie Lund,
Jan T. Kielstein,
Renke Maas,
Robin Schmidt-Haupt,
Michaela Pekarová,
Olaf Hellwinkel,
Dimitrios Tsikas,
Louis G. D’Alecy,
Denise Lau,
Stephan Willems,
Lukáš Kubala,
Heimo Ehmke,
Thomas Meinertz,
Stefan Blankenberg,
Edzard Schwedhelm,
Crystal A. Gadegbeku,
Rainer H. Böger,
Stephan Baldus,
Karsten Sydow
Publication year - 2011
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.111.060541
Subject(s) - myeloperoxidase , nitric oxide , asymmetric dimethylarginine , nitric oxide synthase , chemistry , nadph oxidase , in vivo , biochemistry , lipopolysaccharide , pharmacology , medicine , endocrinology , inflammation , arginine , oxidative stress , biology , microbiology and biotechnology , amino acid
The nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and the leukocyte-derived hemoprotein myeloperoxidase (MPO) are associated with cardiovascular diseases. Activation of monocytes and polymorphonuclear neutrophils (PMNs) with concomitant release of MPO is regulated in a nitric oxide-dependent fashion. The aim of the study was to investigate a potential 2-way interaction between ADMA and MPO.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom